• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.

作者信息

Wu Tzong-Yow, Chen Pao-Yu, Wang Jann-Tay, Liu Wang-Da, Chen Yee-Chun, Chang Shan-Chwen

机构信息

Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 100, Taiwan.

Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.

出版信息

J Antimicrob Chemother. 2024 May 2;79(5):1196-1200. doi: 10.1093/jac/dkae082.

DOI:10.1093/jac/dkae082
PMID:38538154
Abstract
摘要

相似文献

1
Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.替沙格韦单抗/西加韦单抗与瑞德西韦联合治疗对免疫功能低下患者持续性SARS-CoV-2感染的反应欠佳。
J Antimicrob Chemother. 2024 May 2;79(5):1196-1200. doi: 10.1093/jac/dkae082.
2
Comment on: Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.关于：替沙格韦单抗/西加韦单抗与瑞德西韦联合治疗免疫功能低下患者持续性SARS-CoV-2感染疗效欠佳的评论
J Antimicrob Chemother. 2024 Sep 3;79(9):2400-2402. doi: 10.1093/jac/dkae234.
3
Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study.索托维单抗与奈玛特韦/利托那韦或瑞德西韦早期联合使用，在患有轻至中度新冠肺炎的免疫功能低下门诊患者中，持续性严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染率较低：一项前瞻性单中心研究。
Ann Med. 2025 Dec;57(1):2439541. doi: 10.1080/07853890.2024.2439541. Epub 2024 Dec 11.
4
Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir.严重免疫功能低下患者接受多疗程瑞德西韦治疗后，SARS-CoV-2 持续复制。
Int J Infect Dis. 2021 Mar;104:379-381. doi: 10.1016/j.ijid.2020.12.050. Epub 2020 Dec 21.
5
Update Alert 2: Remdesivir for Adults With COVID-19.最新警报2：用于成人新冠肺炎患者的瑞德西韦。
Ann Intern Med. 2021 Dec;174(12):W114-W115. doi: 10.7326/L21-0600. Epub 2021 Oct 5.
6
Remdesivir (Veklury) for the Treatment of COVID-19 in Hospitalized Patients.瑞德西韦（Veklury）用于治疗住院的 COVID-19 患者。
Am Fam Physician. 2021 Sep 1;104(3):311-312.
7
Update Alert 2: Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2).最新警报2：瑞德西韦是否应用于治疗新型冠状病毒肺炎患者？美国医师协会的快速实用要点（第2版）
Ann Intern Med. 2021 Dec;174(12):W116-W117. doi: 10.7326/L21-0607. Epub 2021 Oct 5.
8
Antiviral combination regimens as rescue therapy in immunocompromised hosts with persistent COVID-19.抗病毒联合治疗方案作为持续性新冠肺炎免疫功能低下宿主的挽救治疗
J Chemother. 2025 Apr;37(2):130-134. doi: 10.1080/1120009X.2024.2367935. Epub 2024 Jun 14.
9
Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1).瑞德西韦是否应用于治疗 COVID-19 患者？美国医师学会的快速实践要点（第 1 版）。
Ann Intern Med. 2021 Feb;174(2):229-236. doi: 10.7326/M20-5831. Epub 2020 Oct 5.
10
Successful management of persistent COVID-19 using combination antiviral therapy (nirmatrelvir/ritonavir and remdesivir) and intravenous immunoglobulin transfusion in an immunocompromised host who had received CD20 depleting therapy for follicular lymphoma.在接受滤泡性淋巴瘤 CD20 耗竭治疗的免疫功能低下宿主中，使用联合抗病毒治疗（尼马曲韦/利托那韦和瑞德西韦）和静脉注射免疫球蛋白输注成功治疗持续性 COVID-19。
J Infect Chemother. 2024 Aug;30(8):793-795. doi: 10.1016/j.jiac.2024.01.008. Epub 2024 Jan 17.

引用本文的文献

1
The evolving landscape of COVID-19: factors associated with in-hospital COVID-19 related mortality during the 2023-2024 phase of JN.1 subvariant dominance.新冠病毒疾病（COVID-19）的演变态势：与JN.1亚变体主导的2023 - 2024阶段住院COVID-19相关死亡率相关的因素
BMC Infect Dis. 2025 Jan 27;25(1):130. doi: 10.1186/s12879-025-10480-x.